Core Insights - The article discusses the launch of Novo Nordisk's long-acting recombinant factor VIII, Nuwiq®, in mainland China, marking a significant advancement in the treatment of Hemophilia A [3] Group 1: Product Overview - Nuwiq® is the first and only long-acting recombinant factor VIII approved in China, filling a gap in the treatment of Hemophilia A and enhancing patient accessibility to medication [3] - The product has shown a half-life extension to 19 hours, which is 1.6 times longer than standard formulations, reducing intravenous injection frequency by 50%-71% [2] - Clinical trials in China demonstrated a zero annual bleeding rate (ABR) of 0.00, with 69.4% of patients achieving zero bleeding status and a 94.8% success rate in stopping bleeding [4] Group 2: Market Impact - The inclusion of Nuwiq® in the new national medical insurance directory significantly lowers the treatment burden for patients, addressing the issue of affordability for innovative drugs [4] - Novo Nordisk aims to continue improving drug accessibility for Hemophilia patients in China, contributing to the "Healthy China 2030" initiative [4]